跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FLT3 inhibitors (acute myeloid leukemia)
首页
药物
FLT3 inhibitors (acute myeloid leukemia)
FLT3 inhibitors (acute myeloid leukemia)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA
申请人: UNIV WUERZBURG J MAXIMILIANS
优先权: 2017
CN
EP
2 件公开
USE OF MULTI-TARGET PROTEIN KINASE INHIBITOR
申请人: CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD
优先权: 2019
EP
FLT3 kinase inhibitors
申请人: SHOUYAO HOLDINGS BEIJING CO LTD
优先权: 2022
CN
NOVEL INDIRUBIN DERIVATIVE HAVING HETEROBICYCLIC RESIDUE AND USE THEREOF
申请人: PELEMED CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
COMBINATIONS FOR TREATMENT OF CANCER
申请人: SYNDAX PHARMACEUTICALS INC
优先权: 2021
EP
US
2 件公开
NOVEL FLT3 ANTIBODIES AND ANTIBODY-DRUG-CONJUGATES BASED THEREON, THERAPEUTIC METHODS AND USES THEREOF IN COMBINATION WITH TYROSINE KINASE INHIBITORS
申请人: TUBULIS GMBH
优先权: 2021
EP
US
WO
3 件公开
Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
申请人: UNIV REGENSBURG
优先权: 2017
US
APPLICATION OF GILTERITINIB TO VARIOUS MUTANTS
申请人: JAPANESE FOUND FOR CANCER RES
优先权: 2021
CN
EP
US
3 件公开
药物
反馈
